ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1032

Performance of the European Kidney Function Consortium (EKFC) Creatinine-Based Equation in American Cohorts

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Delanaye, Pierre, Universite de Liege, Liege, Belgium
  • Rule, Andrew D., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Schaeffner, Elke, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Cavalier, Etienne, Universite de Liege, Liege, Belgium
  • Nyman, Ulf, Lunds Universitet, Lund, Sweden
  • Björk, Jonas, Lunds Universitet, Lund, Sweden
  • Pottel, Hans, Universite de Liege, Liege, Belgium

Group or Team Name

  • EKFC (European Kidney Function Consortium).

The new creatinine-based European Kidney Function Consortium (EKFC) equation has been developed and validated in datasets of European subjects. This equation is based on rescaled creatinine, with the rescaling factor (Q-value) which is the median normal value of serum creatinine in a given population. The EKFC equation performed well across the whole age spectrum. However, the validation was limited in Black and non-Black Americans.


Cross-sectional analysis with separate pooled datasets for validation from 9 US research and clinical studies with measured GFR, age, sex, and self-reported race available. Two strategies were considered with population specific Q-values in Black and non-Black men and women (EKFCPS) or a race-free Q value (EKFCRF) which is the mean of the Q values obtained in Black and non-black populations. Performance (bias, precision and accuracy within 30% (P30) was compared with the CKD-EPI2021 equation.


In the whole adult population (n=12,854), the EKFCPS equation showed no statistical bias (0.14 95%CI [-0.07;0.35] mL/min/1.73m2), and the statistical bias of the EKFCRF (0.74 [0.51;0.94] mL/min/1.73m2) was closer to zero than the CKD-EPI2021 equation (1.22 [0.99;1.47]) mL/min/1.73m2]. The percentage of estimated GFR within 30% of measured GFR was similar for CKD-EPI2021 (79.2% [78.5%-79.9%]) and EKFCRF (80.1% [79.4%-80.7%]) but improved with the EKFCPS equation (81.1% [80.5%-81.8%]).


The EKFC-equation can be used in the USA to estimate GFR incorporating either self-reported race or unknown race at the patient’s discretion per hospital registration records. The performance of the EKFC equation is as at least good as the CKD-EPI2021 equation.